GZMK

Across TCGA pan-cancer cohorts, GZMK mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GZMK data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GZMK mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GZMK expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where GZMK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	III,IV	0.362	0.717	.013	11	view →
CCRCC	OS	Quartile	II,III,IV	0.964	0.740	.004	8	view →
PDAC	OS	Tertile	II,III,IV	0.724	0.944	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GZMK–LUAD (OS)

Open the LUAD breakdown →